Monday, May 31, 2010 7:31:39 AM
Price 2.99
Shares 43,292,642
MCap 129.445
PE 6.1
EPS 0.49
Revenue QoQ -22.88%
Revenue YoY 16.24%
Income QoQ -16.05%
Income YoY 16.58%
P/B 1.34
P/R 2.04
P/C 6.14
P/E 6.25
Equity/Share 2.23
CAGR 2009 2008 2007 2006
41.37% Revenue 61.7 50.97 33.19 21.84
33.05% Income 20.23 17.83 12.82 8.59
52.70% Equity/Share 2.14 1.74 1.07 0.60
6.79% Share 42.28 40.22 37.26 34.72
63.06% Equity 90.4 69.87 39.76 20.85
Recent CPHI News
- China Pharma Holdings, Inc. expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025 • PR Newswire (US) • 08/19/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:05:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 08:05:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:06:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:05:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 09:05:47 PM
- China Pharma Holdings Inc. Announces 1-for-5 Reverse Stock Split • PR Newswire (US) • 02/23/2024 09:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/15/2024 05:15:15 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 09:05:11 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/06/2024 09:16:44 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/26/2024 10:04:49 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/12/2024 09:05:53 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/12/2024 07:42:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 09:05:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 09:05:21 PM
- China Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device • PR Newswire (US) • 11/29/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:05:58 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/07/2023 09:05:29 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 10/27/2023 08:06:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/19/2023 08:06:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2023 08:05:11 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM